ClinicalTrials.gg
TerminatedNCT00171938Updated Feb 24, 2017

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

A Phase 2 interventional study of imatinib mesylate in Glioblastoma, sponsored by Novartis. Terminated at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-24.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Apr 2004, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing imatinib in Glioblastoma — none open to participants now, none under way, none of them phase 3. imatinib · Glioblastoma.

Enrollment
7th of 10
30 · median 65
Started
2004
with 2 others
Phase 2
5 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
2 of 10
Novartis

Among the 10 studies testing imatinib in Glioblastoma, this one is the 7th largest by enrollment, is one of 3 that started in 2004, is one of 5 in phase 2, and was the 4th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

None of the 10 studies testing imatinib in Glioblastoma is open now. The open studies under Glioblastoma, anywhere →

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing imatinib in Glioblastoma as a file.
02

Study summary

This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months

03

Conditions studied

  • Glioblastoma

Keywords

  • Glioblastoma
  • Brain tumors
  • Imatinib
  • PDGFR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. documented diagnosis of GBM.
  2. Immunohistochemical documentation of expression of PDGFR.
  3. Unresectable, recurrent disease by MRI and spectroscopy

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any other agents within 28 days of first day of study drug dosing.
  2. Concurrent chemotherapy.
  3. Concurrent radiotherapy.

Other protocol-defined exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 months

Secondary outcomes

  1. Objective Tumoral Response defined by RECISt criteria performed by MRI

  2. OS (overall survival)

07

Study locations

1 site
  • Rio Grande, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2004 to primary completion in Jun 2006, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 15, 2005
StartActual
Apr 2004
Primary completionActual
Jun 2006
CompletionActual
Jun 2006
Last update
Feb 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00171938
Lead sponsor
Novartis
First posted
Sep 15, 2005
Start date
Apr 2004
Primary completion
Jun 2006
Completion
Jun 2006
Last update
Feb 24, 2017

Study contacts

Novartis
study chair · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion